VIDEO: Dyadic International Inc., President, Chief Executive Off

VIDEO: Dyadic International Inc., President, Chief Executive Officer and Director Mark A. Emalfarb and Chief Commercial Officer Matthew Jones Featured in OTCQX Video Series

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE OTC Markets Group Inc.

NEW YORK, March 6, 2018 /PRNewswire/ -- Dyadic International, Inc. (OTCQX: DYAI) President, CEO and Director Mark A. Emalfarb, and Chief Commercial Officer Matthew S. Jones, were interviewed by OTC Markets Group (OTCQX: OTCM) in its prominent OTCQX® Video Series. The series features interviews with senior executives of OTCQX companies as they showcase their businesses and investment profiles.

In the interview, President, CEO and Director Mark A. Emalfarb and Chief Commercial Officer Matthew S. Jones discussed:

  • Dyadic's transition into the biopharmaceutical industry after its sale of its industrial biotech business to DuPont for $ 75 million.
  • Dyadic's efforts to leverage its industrially proven C1 technology to challenge the established methods of manufacturing biologics in order to speed up the development & lower the cost of biologic vaccines & drugs to make them more accessible and affordable to patients while reducing the financial burden on the global healthcare system.
  • Highlights on Dyadic's efforts in using its C1 platform to help develop a potentially lower cost, better performing flu (influenza) vaccine.
  • The further strengthening of its board of directors.

To watch the complete interview, visit OTC Markets Group's YouTube page at:

About Dyadic International, Inc. 
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.  Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of using these technologies in the development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic in the Company's annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed

The information contained in this press release and in the video to which it refers is provided "as is" for educational and informational purposes only, and should not serve as the basis for any trading or investing decisions. OTC Markets Group makes no representations and disclaims all express, implied and statutory warranties of any kind to any viewer or third party.  Neither OTC Markets Group nor any of its affiliates makes any endorsement of any particular company, security, product or financial strategy, and nothing contained in this video should be construed as investment advice.  Investors should undertake their own diligence and carefully evaluate companies before investing.   

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428,  

OTC Markets Group logo. (PRNewsFoto/OTC Markets Group)

Cision View original content with multimedia:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly